Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01039376




Registration number
NCT01039376
Ethics application status
Date submitted
23/12/2009
Date registered
25/12/2009
Date last updated
30/07/2019

Titles & IDs
Public title
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
Scientific title
A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy
Secondary ID [1] 0 0
COMB157C2301
Secondary ID [2] 0 0
112517
Universal Trial Number (UTN)
Trial acronym
PROLONG
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Leukaemia, Lymphocytic, Chronic 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Ofatumumab
Other interventions - Observation

Experimental: ARM A: Ofatumumab - 300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)

Other: ARM B: Observation and assessments as per Arm A - Disease status assessments to determine subject response or progression performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria


Treatment: Other: Ofatumumab
Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.

Other interventions: Observation
Observation/Safety Evaluation
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival, as Assessed by the Investigator
Timepoint [1] 0 0
From randomization until progression or death (up to 79 months)
Primary outcome [2] 0 0
Progression-free Survival, as Assessed by the Independent Review Committee (IRC)
Timepoint [2] 0 0
From randomization until progression or death (up to 79 months)
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
From randomization until death (up to 88 months)
Secondary outcome [2] 0 0
Number of Participants With Improvement in Response From Baseline
Timepoint [2] 0 0
From Baseline until the end of the study (up to 88 months)
Secondary outcome [3] 0 0
Time to Next Therapy
Timepoint [3] 0 0
From randomization until the end of the study (up to 88 months)
Secondary outcome [4] 0 0
Progression-free Survival After Next-line Therapy
Timepoint [4] 0 0
From randomization until progression or death (up to 88 months)
Secondary outcome [5] 0 0
Time to Progression After Next-line Therapy
Timepoint [5] 0 0
From randomization until progression or death (up to 88 months)
Secondary outcome [6] 0 0
Change From Baseline (BL) in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)
Timepoint [6] 0 0
From randomization until the end of the study (up to 47 months)
Secondary outcome [7] 0 0
Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score
Timepoint [7] 0 0
From randomization until the end of the study (up to 47 months)
Secondary outcome [8] 0 0
Change From Baseline in the Quality of Life Status as Assessed by the EuroQol-5D (EQ-5D) Scale
Timepoint [8] 0 0
From screening until the end of the study (up to 47 months)
Secondary outcome [9] 0 0
Number of Participants With an Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status at the Indicated Time Points
Timepoint [9] 0 0
From randomization until the end of the study (up to 88 months)
Secondary outcome [10] 0 0
Number of Participants With the Indicated Constitutional or B-symptoms at the Indicated Time Points
Timepoint [10] 0 0
From Screening until the end of the study (up to 88 months)
Secondary outcome [11] 0 0
Number of Participants With Grade 3 and Above Adverse Event of Infection
Timepoint [11] 0 0
From first dose of study medication until 60 days after the last dose of study medication or until the last observation at Visit 14 (up to 26 months)
Secondary outcome [12] 0 0
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
Timepoint [12] 0 0
From first dose of study medication until 60 days after the last dose of study medication or until the last observation at Visit 14 for AEs (up to 26 months) and until end of study for SAEs (88 months)
Secondary outcome [13] 0 0
Number of Participants With a Grade 3 or Grade 4 Myelosuppression (Anemia, Neutropenia, or Thrombocytopenia) at Indicated Time Points
Timepoint [13] 0 0
From first dose of study medication until 60 days after the last dose of study medication or until the last observation at Visit 14 for AEs (up to 26 months) and until the end of the study for SAEs (88 months)
Secondary outcome [14] 0 0
Number of Participants Who Received at Least One Transfusion During the Study
Timepoint [14] 0 0
From randomization until the end of the study (up to 88 months)
Secondary outcome [15] 0 0
Number of Participants Diagnosed With Autoimmune Hemolytic Anemia (AIHA)
Timepoint [15] 0 0
From randomization until the end of the study (up to 88 months)
Secondary outcome [16] 0 0
Number of Participants With a Positive Anti-ofatumumab Antibody (Human Anti-human Antibody; HAHA) Result
Timepoint [16] 0 0
Pre-dose (Visit 1), Months 7, 13, 19, and 25 during treatment and at 3 and 6 months after last ofatumumab dose (up to 30 months)
Secondary outcome [17] 0 0
Mean Change From Baseline in the Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM at Indicated Time Points
Timepoint [17] 0 0
Baseline, every six months during treatment, and after last treatment visit and/or upon relapse (up to 88 months)
Secondary outcome [18] 0 0
Number of Participants Who Were Positive and Negative for Minimal Residual Disease (MRD) at Any Visit
Timepoint [18] 0 0
From randomization until the end of the study (up to 88 months)
Secondary outcome [19] 0 0
Change From Baseline in Cluster of Differentiation (CD) CD5+CD19+ and CD5-CD19+ Cell Counts at the Indicated Time Points
Timepoint [19] 0 0
Baseline and every two months from Month 3 until Month 25 and at every followup (up to 88 months)
Secondary outcome [20] 0 0
Summary of Covariates to Compute Cox Proportional Hazards Regression Model for Relationship Between Investigator Assessed Progression-free Survival and the Indicated Prognostic Markers
Timepoint [20] 0 0
From Baseline until the end of the study (up to 79 months)
Secondary outcome [21] 0 0
Cmax and Ctrough of Ofatumumab
Timepoint [21] 0 0
Day 1 of Month 1 (Cycle 1 Week 1); Day 8 of Month 1 (Cycle 1 Week 2); and Month 7 (Cycle 4)
Secondary outcome [22] 0 0
Total Plasma Clearance (CL) of Ofatumumab
Timepoint [22] 0 0
Day 1 of Month 1 (Cycle 1 Week 1); Day 8 of Month 1 (Cycle 1 Week 2); and Month 7 (Cycle 4)
Secondary outcome [23] 0 0
AUC(0-tau) of Ofatumumab
Timepoint [23] 0 0
Day 1 of Month 1 (Cycle 1 Week 1); Day 8 of Month 1 (Cycle 1 Week 2); and Month 7 (Cycle 4)
Secondary outcome [24] 0 0
Vss of Ofatumumab
Timepoint [24] 0 0
Day 1 Month 1 ( Cycle 1) through Month 7 ( Cycle 4)
Secondary outcome [25] 0 0
Plasma Half-life (t1/2) of Ofatumumab
Timepoint [25] 0 0
Day 1 of Month 1 (Cycle 1 Week 1); Day 8 of Month 1 (Cycle 1 Week 2); and Month 7 (Cycle 4)

Eligibility
Key inclusion criteria
* Adults with documented diagnosis of CLL based on the modified IWCLL updated NCI-WG guidelines (Hallek, 2008)
* At least PR according to the revised 2008 NCI-WG CLL criteria, within 3 months of the response assessment after the last dose of 2nd/3rd line treatment
* The anti-leukemic treatment before study entry should have been at least 3 months or 3 cycles
* ECOG Performance Status of 0-2
* Signed written informed consent prior to performing any study-specific procedures
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Known primary or secondary fludarabine-refractory subjects, defined as treatment failure (failure to achieve a CR or PR) or disease progression within 6 months
* Prior maintenance therapy
* Known transformation of CLL (eg.Richter's transformation), prolymphocytic leukemia (PLL), or CNS involvement of CLL
* Active Autoimmune hemolytic anemia (AIHA) requiring treatment except if in the opinion of the investigator and medical monitor it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data
* Previous autologous or allogeneic stem cell transplantation
* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis B or C
* Other past or current malignancy (with the exception of basal cell carcinoma or the skin or in situ carcinoma of the cervix or breasts) unless the tumor was successfully treated with curative intent at least 2 years prior to trial entry except if in the opinion of the investigator and medical monitor it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data
* Clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months prior to screening, congestive heart failure, and arrhythmia requiring therapy, with the exception of exta systoles or minor conduction abnormalities except if in the opinion of the investigator and medical monitor it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data
* History of significant cerebrovascular disease or event with symptoms or sequelae
* Significant concurrent, uncontrolled medical condition that in the opinion of the investigator or GSK medical monitor contraindicates participation in this study
* Other anti-leukemic use of medications including glucocorticoids
* Known HIV positive
* Screening laboratory values: platelets <50 x 10x9/L, neutrophils<1.0 x 10x9/L, Creatinine > 1.5 X upper normal limit (unless normal creatinine clearance), total bilirubin >1.5 X upper normal limit, ALT >2.5 X upper normal limit (unless due to liver involvement of CLL), alkaline phosphase > 2.5 X upper normal limit
* Known or suspected hypersensitivity to ofatumumab that in the opinion of the investigator or medical monitor contraindicates study participation
* Subjects who have received treatment with any non-marketed drug substance or experimental therapy within 5-terminal half-lives or 4 weeks whichever is longer prior to first dose of study medication or currently participating in any other interventional clinical study
* Lactating women, women with a positive pregnancy test at Visit 1 or women (of childbearing potential) as well as men with partners of childbearing potential, who are not willing to use adequate contraception from study start through one year following last ofatumumab dose. Adequate contraception is defined as abstinence, oral hormonal birth control, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device, and male partner sterilization if male partner is sole partner for that subject. For females in the USA, the use of a double barrier method is also considered adequate (condom or occlusive cap plus spermicidal agent).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/05/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/06/2018
Sample size
Target
Accrual to date
Final
480
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Darlinghurst
Recruitment hospital [2] 0 0
Novartis Investigative Site - Randwick
Recruitment hospital [3] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [4] 0 0
Novartis Investigative Site - East Melbourne
Recruitment hospital [5] 0 0
Novartis Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Santa Fe
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad Autonoma de Buenos Aires
Country [28] 0 0
Belgium
State/province [28] 0 0
Antwerpen
Country [29] 0 0
Belgium
State/province [29] 0 0
Brugge
Country [30] 0 0
Belgium
State/province [30] 0 0
Brussels
Country [31] 0 0
Belgium
State/province [31] 0 0
Gent
Country [32] 0 0
Belgium
State/province [32] 0 0
Hasselt
Country [33] 0 0
Belgium
State/province [33] 0 0
Roeselare
Country [34] 0 0
Belgium
State/province [34] 0 0
Wilrijk
Country [35] 0 0
Brazil
State/province [35] 0 0
Bahía
Country [36] 0 0
Brazil
State/province [36] 0 0
Goiás
Country [37] 0 0
Brazil
State/province [37] 0 0
Rio Grande Do Sul
Country [38] 0 0
Brazil
State/province [38] 0 0
São Paulo
Country [39] 0 0
Canada
State/province [39] 0 0
Alberta
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Canada
State/province [41] 0 0
Quebec
Country [42] 0 0
Canada
State/province [42] 0 0
Saskatchewan
Country [43] 0 0
Czechia
State/province [43] 0 0
Brno
Country [44] 0 0
Czechia
State/province [44] 0 0
Hradec Kralove
Country [45] 0 0
Czechia
State/province [45] 0 0
Olomouc
Country [46] 0 0
Czechia
State/province [46] 0 0
Pelhrimov
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 10
Country [48] 0 0
Denmark
State/province [48] 0 0
Herlev
Country [49] 0 0
Denmark
State/province [49] 0 0
Kobenhavn
Country [50] 0 0
Denmark
State/province [50] 0 0
Roskilde
Country [51] 0 0
Finland
State/province [51] 0 0
Helsinki
Country [52] 0 0
Finland
State/province [52] 0 0
Jyvaskyla
Country [53] 0 0
Finland
State/province [53] 0 0
Pori
Country [54] 0 0
Finland
State/province [54] 0 0
Tampere
Country [55] 0 0
Finland
State/province [55] 0 0
Turku
Country [56] 0 0
France
State/province [56] 0 0
Blois cedex
Country [57] 0 0
France
State/province [57] 0 0
Caen cedex 5
Country [58] 0 0
France
State/province [58] 0 0
Clermont-Ferrand Cedex 1
Country [59] 0 0
France
State/province [59] 0 0
Dijon
Country [60] 0 0
France
State/province [60] 0 0
Lille cedex
Country [61] 0 0
France
State/province [61] 0 0
Marseille Cedex 9
Country [62] 0 0
France
State/province [62] 0 0
Mulhouse
Country [63] 0 0
France
State/province [63] 0 0
Pessac cedex
Country [64] 0 0
France
State/province [64] 0 0
Saint Pierre cedex
Country [65] 0 0
France
State/province [65] 0 0
Strasbourg cedex
Country [66] 0 0
France
State/province [66] 0 0
Toulouse cedex 9
Country [67] 0 0
France
State/province [67] 0 0
Vandoeuvre-Les-Nancy
Country [68] 0 0
Greece
State/province [68] 0 0
Athens,
Country [69] 0 0
Greece
State/province [69] 0 0
Athens
Country [70] 0 0
Greece
State/province [70] 0 0
Piraeus
Country [71] 0 0
Greece
State/province [71] 0 0
Thessaloniki
Country [72] 0 0
Hungary
State/province [72] 0 0
Budapest
Country [73] 0 0
Hungary
State/province [73] 0 0
Debrecen
Country [74] 0 0
Hungary
State/province [74] 0 0
Kecskemet
Country [75] 0 0
Hungary
State/province [75] 0 0
Szeged
Country [76] 0 0
India
State/province [76] 0 0
Ahmedabad
Country [77] 0 0
India
State/province [77] 0 0
Mumbai
Country [78] 0 0
India
State/province [78] 0 0
Pune
Country [79] 0 0
Israel
State/province [79] 0 0
Afula
Country [80] 0 0
Israel
State/province [80] 0 0
Haifa
Country [81] 0 0
Israel
State/province [81] 0 0
Jerusalem
Country [82] 0 0
Israel
State/province [82] 0 0
Kfar Saba
Country [83] 0 0
Israel
State/province [83] 0 0
Nahariya
Country [84] 0 0
Israel
State/province [84] 0 0
Petach-Tikva
Country [85] 0 0
Israel
State/province [85] 0 0
Ramat Gan
Country [86] 0 0
Israel
State/province [86] 0 0
Rehovot
Country [87] 0 0
Israel
State/province [87] 0 0
Tel-Aviv
Country [88] 0 0
Israel
State/province [88] 0 0
Zrifin
Country [89] 0 0
Italy
State/province [89] 0 0
Emilia-Romagna
Country [90] 0 0
Italy
State/province [90] 0 0
Lazio
Country [91] 0 0
Italy
State/province [91] 0 0
Piemonte
Country [92] 0 0
Italy
State/province [92] 0 0
Toscana
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Seoul
Country [94] 0 0
Netherlands
State/province [94] 0 0
Amersfoort
Country [95] 0 0
Netherlands
State/province [95] 0 0
Amsterdam
Country [96] 0 0
Netherlands
State/province [96] 0 0
Blaricum
Country [97] 0 0
Netherlands
State/province [97] 0 0
Breda
Country [98] 0 0
Netherlands
State/province [98] 0 0
Den Bosch
Country [99] 0 0
Netherlands
State/province [99] 0 0
Den Haag
Country [100] 0 0
Netherlands
State/province [100] 0 0
Deventer
Country [101] 0 0
Netherlands
State/province [101] 0 0
Dordrecht
Country [102] 0 0
Netherlands
State/province [102] 0 0
Enschede
Country [103] 0 0
Netherlands
State/province [103] 0 0
Groningen
Country [104] 0 0
Netherlands
State/province [104] 0 0
Hoofddorp
Country [105] 0 0
Netherlands
State/province [105] 0 0
Leiden
Country [106] 0 0
Netherlands
State/province [106] 0 0
Maastricht
Country [107] 0 0
Netherlands
State/province [107] 0 0
Rotterdam
Country [108] 0 0
Netherlands
State/province [108] 0 0
Sittard-geleen
Country [109] 0 0
Netherlands
State/province [109] 0 0
Tilburg
Country [110] 0 0
Norway
State/province [110] 0 0
Oslo
Country [111] 0 0
Poland
State/province [111] 0 0
Bialystok
Country [112] 0 0
Poland
State/province [112] 0 0
Chorzow
Country [113] 0 0
Poland
State/province [113] 0 0
Slupsk
Country [114] 0 0
Poland
State/province [114] 0 0
Szczecin
Country [115] 0 0
Poland
State/province [115] 0 0
Warszawa
Country [116] 0 0
Poland
State/province [116] 0 0
Wroclaw
Country [117] 0 0
Puerto Rico
State/province [117] 0 0
San Juan
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Kazan
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Moscow
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Novosibirsk
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Penza
Country [122] 0 0
Russian Federation
State/province [122] 0 0
St'Petersburg
Country [123] 0 0
Russian Federation
State/province [123] 0 0
St. Petersburg
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Volgograd
Country [125] 0 0
Spain
State/province [125] 0 0
Hospitalet de Llobregat (Barcelona)
Country [126] 0 0
Spain
State/province [126] 0 0
Madrid
Country [127] 0 0
Spain
State/province [127] 0 0
Salamanca
Country [128] 0 0
Spain
State/province [128] 0 0
Sevilla
Country [129] 0 0
Spain
State/province [129] 0 0
Toledo
Country [130] 0 0
Spain
State/province [130] 0 0
Zaragoza
Country [131] 0 0
Sweden
State/province [131] 0 0
Goteborg
Country [132] 0 0
Sweden
State/province [132] 0 0
Linkoping
Country [133] 0 0
Sweden
State/province [133] 0 0
Lulea
Country [134] 0 0
Sweden
State/province [134] 0 0
Orebro
Country [135] 0 0
Sweden
State/province [135] 0 0
Stockholm
Country [136] 0 0
Sweden
State/province [136] 0 0
Uppsala
Country [137] 0 0
Turkey
State/province [137] 0 0
Ankara
Country [138] 0 0
Turkey
State/province [138] 0 0
Istanbul
Country [139] 0 0
Turkey
State/province [139] 0 0
Izmir
Country [140] 0 0
Ukraine
State/province [140] 0 0
Cherkasy
Country [141] 0 0
Ukraine
State/province [141] 0 0
Dnipropetrovsk
Country [142] 0 0
Ukraine
State/province [142] 0 0
Kharkiv
Country [143] 0 0
Ukraine
State/province [143] 0 0
Khmelnytskyi
Country [144] 0 0
Ukraine
State/province [144] 0 0
Kyiv
Country [145] 0 0
Ukraine
State/province [145] 0 0
Lviv
Country [146] 0 0
Ukraine
State/province [146] 0 0
Makiivka
Country [147] 0 0
Ukraine
State/province [147] 0 0
Vinnitsa
Country [148] 0 0
Ukraine
State/province [148] 0 0
Zhytomyr

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment. This study would also evaluate the safety of ofatumumab maintenance compared to observation (the current standard of care). This study was co-developed with the HOVON and NORDIC CLL group and would be conducted as a collaborative effort with GSK.
Trial website
https://clinicaltrials.gov/study/NCT01039376
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01039376